Single-use purification platform expected to improve biologics manufacturing

The platform is designed to increase manufacturing productivity, while its single-use design is expected to further support reduction of validation time and cost.

Oct. 30, 2015
2 min read

A new bioprocessing purification platform is one step closer to market after developer Puridify Ltd. closed a £2.2 million ($3.4 million) Series A funding round.

Puridify’s purification technology, known as FibroSelect, aims to transform purification in bioprocess manufacturing. The platform is designed to increase manufacturing productivity, while its single-use design is expected to further support reduction of validation time and cost.

The technology was developed during a collaborative research project between the Advanced Centre for Biochemical Engineering at UCL (University College London) and the U.K.’s Science & Technology Facilities Council.

Puridify plans to use the Series A funding to accelerate the commercialization of its nanofibre-based purification technology with the aim of having GMP compatible purification units ready for wider industry use in 2016.

The follow-on investment by existing investors Imperial Innovations, SR One and UCL Business takes the total raised including grant funding to £8 million ($12.3 million).

“We are delighted that our investors and Innovate UK are continuing to support us as we look to further expand our team and focus on generating industry relevant end-user data for FibroSelect, while rapidly establishing a manufacturing basis for GMP-compliant products,” commented Dr. Oliver Hardick, CEO of Puridify.

“Our single-use purification units will enable this technology to effectively service the wider Life Sciences industry. Specifically, collaborations with biotherapeutic drug manufacturers are already proving the benefit of FibroSelect as a single-use high productivity product capture platform, suitable for existing and emergent biologic therapies.”

Dr. Inga Deakin, associate for Healthcare Ventures at Imperial Innovations, added: “The FibroSelect purification platform is ideally suited to support the industry’s increasing interest in single use and demand for smaller, more flexible manufacturing facilities that can produce multiple products.”

About the Author

Sign up for Processing Magazine eNewsletters
Get the latest news and updates